Concepts (235)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Bone Density Conservation Agents | 41 | 2024 | 791 | 9.660 |
Why?
|
Osteoporosis, Postmenopausal | 28 | 2024 | 399 | 9.520 |
Why?
|
Teriparatide | 31 | 2024 | 225 | 8.640 |
Why?
|
Bone Density | 47 | 2024 | 3491 | 4.260 |
Why?
|
Alendronate | 11 | 2024 | 174 | 3.090 |
Why?
|
Osteoporosis | 22 | 2024 | 1581 | 2.760 |
Why?
|
Bone Remodeling | 15 | 2024 | 577 | 2.360 |
Why?
|
Parathyroid Hormone-Related Protein | 6 | 2021 | 327 | 2.310 |
Why?
|
Osteoporotic Fractures | 9 | 2024 | 415 | 2.230 |
Why?
|
Diphosphonates | 10 | 2024 | 625 | 1.720 |
Why?
|
Testosterone | 19 | 2020 | 2495 | 1.520 |
Why?
|
Aromatase Inhibitors | 8 | 2013 | 519 | 1.350 |
Why?
|
Spinal Fractures | 4 | 2020 | 702 | 1.190 |
Why?
|
Goserelin | 5 | 2020 | 126 | 1.030 |
Why?
|
Nitriles | 6 | 2009 | 981 | 0.970 |
Why?
|
Triazoles | 6 | 2009 | 902 | 0.950 |
Why?
|
Radius | 4 | 2020 | 441 | 0.950 |
Why?
|
Bone Resorption | 6 | 2019 | 721 | 0.940 |
Why?
|
Estradiol | 10 | 2016 | 1947 | 0.940 |
Why?
|
Bone and Bones | 10 | 2020 | 2559 | 0.930 |
Why?
|
Hypogonadism | 6 | 2009 | 802 | 0.860 |
Why?
|
Femur Neck | 7 | 2024 | 316 | 0.810 |
Why?
|
Parathyroid Hormone | 5 | 2017 | 1791 | 0.800 |
Why?
|
Drug Therapy, Combination | 14 | 2024 | 6306 | 0.790 |
Why?
|
Tibia | 4 | 2020 | 1071 | 0.780 |
Why?
|
Fractures, Bone | 6 | 2024 | 2043 | 0.690 |
Why?
|
Collagen Type I | 12 | 2020 | 616 | 0.680 |
Why?
|
Androstenedione | 5 | 2002 | 138 | 0.660 |
Why?
|
Drug Administration Schedule | 4 | 2024 | 4853 | 0.650 |
Why?
|
Libido | 2 | 2020 | 123 | 0.590 |
Why?
|
Procollagen | 7 | 2016 | 189 | 0.540 |
Why?
|
Postmenopause | 8 | 2024 | 2517 | 0.520 |
Why?
|
Heart Neoplasms | 1 | 2019 | 374 | 0.510 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2019 | 792 | 0.500 |
Why?
|
Critical Pathways | 1 | 2019 | 475 | 0.500 |
Why?
|
Phosphates | 3 | 2012 | 763 | 0.480 |
Why?
|
Fibroblast Growth Factors | 3 | 2012 | 871 | 0.460 |
Why?
|
Absorptiometry, Photon | 8 | 2020 | 1707 | 0.440 |
Why?
|
Anabolic Agents | 3 | 2024 | 256 | 0.420 |
Why?
|
Hypoparathyroidism | 1 | 2013 | 136 | 0.380 |
Why?
|
Lumbar Vertebrae | 7 | 2024 | 1878 | 0.380 |
Why?
|
Follicle Stimulating Hormone | 1 | 2014 | 731 | 0.380 |
Why?
|
Aged | 46 | 2024 | 171344 | 0.380 |
Why?
|
Citalopram | 1 | 2014 | 402 | 0.370 |
Why?
|
Peptides | 11 | 2016 | 4347 | 0.360 |
Why?
|
Bone Morphogenetic Proteins | 2 | 2016 | 845 | 0.350 |
Why?
|
Glucocorticoids | 3 | 2012 | 2158 | 0.340 |
Why?
|
Humans | 86 | 2024 | 766812 | 0.330 |
Why?
|
Middle Aged | 45 | 2024 | 223267 | 0.330 |
Why?
|
Body Composition | 4 | 2013 | 2441 | 0.320 |
Why?
|
Drug Resistance | 1 | 2015 | 1592 | 0.320 |
Why?
|
Muscle Strength | 1 | 2013 | 639 | 0.320 |
Why?
|
Gonadal Steroid Hormones | 2 | 2014 | 706 | 0.300 |
Why?
|
Female | 43 | 2024 | 396532 | 0.290 |
Why?
|
Imidazoles | 3 | 2024 | 1168 | 0.280 |
Why?
|
Osteocalcin | 5 | 2011 | 271 | 0.280 |
Why?
|
Health | 1 | 2009 | 396 | 0.270 |
Why?
|
Calcium | 6 | 2023 | 5783 | 0.270 |
Why?
|
Hypercalcemia | 1 | 2009 | 425 | 0.260 |
Why?
|
Drug Substitution | 3 | 2019 | 292 | 0.250 |
Why?
|
Aromatase | 1 | 2005 | 147 | 0.250 |
Why?
|
Ergocalciferols | 2 | 2015 | 105 | 0.210 |
Why?
|
Placebos | 2 | 2020 | 1659 | 0.210 |
Why?
|
Osteogenesis | 3 | 2024 | 1282 | 0.200 |
Why?
|
Single-Blind Method | 2 | 2017 | 1587 | 0.200 |
Why?
|
Radiography | 3 | 2020 | 6968 | 0.190 |
Why?
|
Treatment Outcome | 15 | 2020 | 65286 | 0.190 |
Why?
|
Double-Blind Method | 8 | 2017 | 12430 | 0.190 |
Why?
|
Peptide Fragments | 6 | 2016 | 5143 | 0.190 |
Why?
|
Aged, 80 and over | 17 | 2024 | 59548 | 0.180 |
Why?
|
Etidronic Acid | 1 | 2000 | 63 | 0.180 |
Why?
|
Dose-Response Relationship, Drug | 7 | 2020 | 10745 | 0.170 |
Why?
|
Osteogenesis Imperfecta | 1 | 2020 | 81 | 0.170 |
Why?
|
RANK Ligand | 3 | 2012 | 321 | 0.170 |
Why?
|
Vitamin D | 2 | 2012 | 3270 | 0.160 |
Why?
|
Androgen Antagonists | 4 | 2012 | 1411 | 0.160 |
Why?
|
Estrogens | 2 | 2004 | 1528 | 0.160 |
Why?
|
Leuprolide | 1 | 2001 | 310 | 0.160 |
Why?
|
Hip | 2 | 2019 | 251 | 0.150 |
Why?
|
Area Under Curve | 3 | 2013 | 1639 | 0.150 |
Why?
|
Genetic Markers | 2 | 2016 | 2603 | 0.150 |
Why?
|
Freedom | 1 | 2018 | 69 | 0.150 |
Why?
|
Male | 40 | 2024 | 364154 | 0.140 |
Why?
|
Tomography, X-Ray Computed | 2 | 2017 | 20710 | 0.140 |
Why?
|
Injections, Subcutaneous | 4 | 2020 | 684 | 0.140 |
Why?
|
Professional Practice | 1 | 2019 | 314 | 0.140 |
Why?
|
Porosity | 1 | 2017 | 347 | 0.130 |
Why?
|
Enzyme Inhibitors | 2 | 2004 | 3723 | 0.130 |
Why?
|
Intention to Treat Analysis | 1 | 2017 | 418 | 0.130 |
Why?
|
Eunuchism | 1 | 2016 | 19 | 0.130 |
Why?
|
Hip Fractures | 1 | 2024 | 996 | 0.130 |
Why?
|
Sex Hormone-Binding Globulin | 2 | 2008 | 557 | 0.130 |
Why?
|
Androgens | 1 | 2003 | 1280 | 0.120 |
Why?
|
Cosmetics | 1 | 2016 | 104 | 0.120 |
Why?
|
Prostatic Neoplasms | 6 | 2012 | 11094 | 0.120 |
Why?
|
Vitamin D Deficiency | 2 | 2015 | 1349 | 0.110 |
Why?
|
Gonads | 1 | 2014 | 109 | 0.110 |
Why?
|
Orthopedics | 1 | 2022 | 906 | 0.110 |
Why?
|
Gastroenterology | 1 | 2000 | 593 | 0.110 |
Why?
|
Lipids | 1 | 2005 | 3322 | 0.110 |
Why?
|
Adaptor Proteins, Signal Transducing | 2 | 2016 | 2902 | 0.110 |
Why?
|
Spine | 2 | 2019 | 1134 | 0.110 |
Why?
|
Bone Development | 2 | 2007 | 470 | 0.110 |
Why?
|
Sex Factors | 1 | 2007 | 10619 | 0.110 |
Why?
|
Risk Reduction Behavior | 1 | 2019 | 1120 | 0.100 |
Why?
|
Hormones | 2 | 2009 | 866 | 0.100 |
Why?
|
Calcitriol | 2 | 2006 | 301 | 0.100 |
Why?
|
Risk Factors | 7 | 2020 | 74889 | 0.100 |
Why?
|
Follow-Up Studies | 4 | 2022 | 39312 | 0.100 |
Why?
|
Antibodies, Monoclonal | 4 | 2022 | 9244 | 0.090 |
Why?
|
Dietary Supplements | 3 | 2015 | 3429 | 0.090 |
Why?
|
Drug Monitoring | 2 | 2019 | 962 | 0.090 |
Why?
|
Estrone | 2 | 2002 | 234 | 0.090 |
Why?
|
Adiposity | 1 | 2020 | 1892 | 0.090 |
Why?
|
Drugs, Investigational | 1 | 2012 | 211 | 0.090 |
Why?
|
Collagen | 3 | 2020 | 2635 | 0.090 |
Why?
|
Medication Adherence | 2 | 2020 | 2190 | 0.080 |
Why?
|
Aging | 3 | 2020 | 8728 | 0.080 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2012 | 1536 | 0.080 |
Why?
|
Administration, Cutaneous | 2 | 2020 | 712 | 0.080 |
Why?
|
Drug Combinations | 2 | 2013 | 2085 | 0.080 |
Why?
|
Administration, Oral | 3 | 2002 | 4019 | 0.080 |
Why?
|
Adult | 17 | 2016 | 223305 | 0.080 |
Why?
|
Multivariate Analysis | 4 | 2012 | 12064 | 0.080 |
Why?
|
Biological Availability | 1 | 2009 | 387 | 0.070 |
Why?
|
Inpatients | 3 | 2023 | 2566 | 0.070 |
Why?
|
Prostatic Diseases | 1 | 2007 | 55 | 0.070 |
Why?
|
Sarcopenia | 1 | 2012 | 378 | 0.070 |
Why?
|
Population Groups | 1 | 2008 | 209 | 0.070 |
Why?
|
Endpoint Determination | 1 | 2009 | 592 | 0.070 |
Why?
|
Osteosarcoma | 1 | 2012 | 908 | 0.070 |
Why?
|
Testis | 1 | 2009 | 786 | 0.060 |
Why?
|
Menopause | 1 | 2014 | 1656 | 0.060 |
Why?
|
Public Health | 1 | 2019 | 2680 | 0.060 |
Why?
|
Dinoprostone | 1 | 2009 | 597 | 0.060 |
Why?
|
Causality | 1 | 2012 | 1252 | 0.060 |
Why?
|
Gonadotropin-Releasing Hormone | 3 | 2009 | 1142 | 0.060 |
Why?
|
Young Adult | 6 | 2016 | 59939 | 0.060 |
Why?
|
Disease Susceptibility | 1 | 2012 | 1791 | 0.060 |
Why?
|
Time Factors | 4 | 2019 | 40149 | 0.060 |
Why?
|
Infusions, Intravenous | 1 | 2009 | 2228 | 0.060 |
Why?
|
Osteoprotegerin | 1 | 2005 | 179 | 0.060 |
Why?
|
Hospitalization | 1 | 2024 | 10816 | 0.060 |
Why?
|
Steroids | 1 | 2009 | 936 | 0.060 |
Why?
|
Risk | 2 | 2015 | 9602 | 0.050 |
Why?
|
Chi-Square Distribution | 2 | 2012 | 3431 | 0.050 |
Why?
|
Vitamins | 1 | 2012 | 1631 | 0.050 |
Why?
|
Patient Education as Topic | 1 | 2013 | 2334 | 0.050 |
Why?
|
Epitestosterone | 1 | 2002 | 3 | 0.050 |
Why?
|
Cardiovascular Diseases | 2 | 2007 | 15652 | 0.050 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2005 | 588 | 0.050 |
Why?
|
Control Groups | 1 | 2002 | 107 | 0.050 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 3803 | 0.050 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2005 | 692 | 0.050 |
Why?
|
Femur | 1 | 2008 | 1318 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2019 | 10384 | 0.050 |
Why?
|
Androsterone | 1 | 2001 | 14 | 0.050 |
Why?
|
Etiocholanolone | 1 | 2001 | 7 | 0.050 |
Why?
|
Glucuronides | 1 | 2001 | 20 | 0.050 |
Why?
|
Hematopoietic Stem Cells | 1 | 2014 | 3408 | 0.050 |
Why?
|
Adipose Tissue | 1 | 2013 | 3317 | 0.050 |
Why?
|
Insulin Resistance | 1 | 2015 | 3989 | 0.050 |
Why?
|
Estranes | 1 | 2000 | 2 | 0.050 |
Why?
|
Combined Modality Therapy | 1 | 2013 | 8540 | 0.050 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2005 | 1131 | 0.050 |
Why?
|
Nandrolone | 1 | 2000 | 16 | 0.050 |
Why?
|
Drug Delivery Systems | 1 | 2012 | 2210 | 0.050 |
Why?
|
Dihydrotestosterone | 1 | 2001 | 194 | 0.040 |
Why?
|
Insulin | 1 | 2015 | 6608 | 0.040 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2005 | 857 | 0.040 |
Why?
|
Penile Erection | 1 | 2020 | 100 | 0.040 |
Why?
|
Physician-Patient Relations | 1 | 2013 | 3266 | 0.040 |
Why?
|
Nonprescription Drugs | 1 | 2000 | 119 | 0.040 |
Why?
|
Acetaminophen | 1 | 2023 | 549 | 0.040 |
Why?
|
Drug Contamination | 1 | 2000 | 151 | 0.040 |
Why?
|
Gels | 1 | 2020 | 420 | 0.040 |
Why?
|
Patient Compliance | 1 | 2009 | 2694 | 0.040 |
Why?
|
Body Fat Distribution | 1 | 2020 | 246 | 0.040 |
Why?
|
Drug Synergism | 1 | 2003 | 1757 | 0.040 |
Why?
|
United States | 4 | 2019 | 72945 | 0.040 |
Why?
|
Creatinine | 1 | 2023 | 1917 | 0.040 |
Why?
|
Alkaline Phosphatase | 1 | 2001 | 855 | 0.040 |
Why?
|
Orchiectomy | 2 | 2009 | 466 | 0.040 |
Why?
|
Glycoproteins | 1 | 2005 | 2201 | 0.040 |
Why?
|
Injections | 1 | 2020 | 839 | 0.030 |
Why?
|
Receptors, G-Protein-Coupled | 1 | 2024 | 1244 | 0.030 |
Why?
|
Models, Biological | 1 | 2013 | 9464 | 0.030 |
Why?
|
Secondary Prevention | 1 | 2022 | 1469 | 0.030 |
Why?
|
Analysis of Variance | 1 | 2005 | 6214 | 0.030 |
Why?
|
Databases, Factual | 1 | 2012 | 8065 | 0.030 |
Why?
|
25-Hydroxyvitamin D 2 | 1 | 2015 | 38 | 0.030 |
Why?
|
Interleukin-6 | 1 | 2005 | 3226 | 0.030 |
Why?
|
Amino Acids | 1 | 2001 | 1711 | 0.030 |
Why?
|
Calcifediol | 1 | 2015 | 156 | 0.030 |
Why?
|
Mesenchymal Stem Cells | 1 | 2024 | 1664 | 0.030 |
Why?
|
Homeostasis | 1 | 2005 | 3343 | 0.030 |
Why?
|
Lymphatic Metastasis | 1 | 2001 | 2901 | 0.030 |
Why?
|
C-Reactive Protein | 1 | 2005 | 3853 | 0.030 |
Why?
|
Extracellular Matrix | 1 | 2020 | 1730 | 0.030 |
Why?
|
Cross-Sectional Studies | 3 | 2008 | 26309 | 0.020 |
Why?
|
Acid Phosphatase | 1 | 2011 | 141 | 0.020 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2015 | 12246 | 0.020 |
Why?
|
Boston | 2 | 2015 | 9346 | 0.020 |
Why?
|
Longitudinal Studies | 2 | 2019 | 14762 | 0.020 |
Why?
|
Cell Count | 1 | 2014 | 1826 | 0.020 |
Why?
|
Cognition | 1 | 2007 | 7057 | 0.020 |
Why?
|
Urinalysis | 2 | 2002 | 369 | 0.020 |
Why?
|
Substance Abuse Detection | 2 | 2002 | 301 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2019 | 2783 | 0.020 |
Why?
|
Immunoassay | 1 | 2012 | 744 | 0.020 |
Why?
|
Chromatography, Liquid | 1 | 2012 | 996 | 0.020 |
Why?
|
Animals | 2 | 2012 | 168939 | 0.020 |
Why?
|
Retreatment | 1 | 2009 | 598 | 0.020 |
Why?
|
Massachusetts | 1 | 2020 | 8890 | 0.020 |
Why?
|
Isoenzymes | 1 | 2011 | 1688 | 0.020 |
Why?
|
Retrospective Studies | 3 | 2020 | 81657 | 0.020 |
Why?
|
Sampling Studies | 1 | 2008 | 614 | 0.020 |
Why?
|
Phenotype | 1 | 2024 | 16722 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2011 | 2846 | 0.020 |
Why?
|
Tandem Mass Spectrometry | 1 | 2012 | 1198 | 0.020 |
Why?
|
Cell Lineage | 1 | 2014 | 2573 | 0.020 |
Why?
|
Cohort Studies | 2 | 2020 | 41706 | 0.010 |
Why?
|
Electronic Health Records | 1 | 2020 | 4880 | 0.010 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2001 | 9407 | 0.010 |
Why?
|
Quality of Life | 1 | 2004 | 13476 | 0.010 |
Why?
|
Linear Models | 1 | 2012 | 5873 | 0.010 |
Why?
|
B-Lymphocytes | 1 | 2014 | 4787 | 0.010 |
Why?
|
Prognosis | 1 | 2019 | 29959 | 0.010 |
Why?
|
Protein Precursors | 1 | 2002 | 1134 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2015 | 15912 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2014 | 10263 | 0.010 |
Why?
|
Mass Spectrometry | 1 | 2000 | 2198 | 0.010 |
Why?
|
Age Factors | 1 | 2008 | 18397 | 0.010 |
Why?
|
Incidence | 1 | 2009 | 21527 | 0.010 |
Why?
|
Algorithms | 1 | 2009 | 14073 | 0.000 |
Why?
|
Concepts
(235)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(29)
People in Profiles who have published with this person.
Explore
_
Similar People
(59)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_